iLoF - Intelligent Lab on Fiber Limited is a digital health company developing an AI-driven platform aimed at speeding up personalised drug discovery and development. The name suggests a lab-on-fiber concept, which typically involves optical sensors and microfluidics, possibly combined with machine learning to analyse biological samples. Public information is sparse, but the company is registered in the UK and holds a Skilled Worker sponsor licence with an A rating, indicating it meets the Home Office standards for recruiting international employees. That status, along with the specialised nature of the work, suggests the company is building a team of scientists and engineers. Without further details, the exact workforce size is unknown, but digital health startups often start with fewer than 50 employees. The core focus appears to be using patient data and AI to match treatments to individuals, improving drug efficacy and reducing adverse reactions. This could involve tissue sample analysis, biomarker detection, and predictive modelling, though these are inferred from the company's stated purpose rather than confirmed. There is no information about international offices or funding. Job seekers should explore current openings on the company's website or LinkedIn. The combination of a niche technology and a UK sponsor licence makes iLoF a plausible option for highly skilled researchers in health technology.

iLoF - Intelligent Lab on Fiber Limited is a digital health company developing an AI-driven platform aimed at speeding up personalised drug discovery and development. The name suggests a lab-on-fiber concept, which typically involves optical sensors and microfluidics, possibly combined with machine learning to analyse biological samples. Public information is sparse, but the company is registered in the UK and holds a Skilled Worker sponsor licence with an A rating, indicating it meets the Home Office standards for recruiting international employees. That status, along with the specialised nature of the work, suggests the company is building a team of scientists and engineers. Without further details, the exact workforce size is unknown, but digital health startups often start with fewer than 50 employees. The core focus appears to be using patient data and AI to match treatments to individuals, improving drug efficacy and reducing adverse reactions. This could involve tissue sample analysis, biomarker detection, and predictive modelling, though these are inferred from the company's stated purpose rather than confirmed. There is no information about international offices or funding. Job seekers should explore current openings on the company's website or LinkedIn. The combination of a niche technology and a UK sponsor licence makes iLoF a plausible option for highly skilled researchers in health technology.